Peabody coal mine workers locked out in wages dispute
About 160 permanent employees were locked out without pay from Wednesday this week to Thursday next week at the Metropolitan Mine in Helensburgh.
The Mining and Energy Union said it would lodge a claim for a 15 per cent wage increase over three years, a one-off market rate increase of $1.50 per hour, plus a $4 increase to crib payments.
The president of the union's NSW South West District, Mark Jenkins, said mine owner Peabody was punishing workers for exercising their industrial rights as they sought to negotiate a new enterprise agreement.
"The workers enacted their industrial right and took some limited one-hour stoppages across their shifts," he said.
Mr Jenkins said there was no warning.
"We went into a bargaining meeting with the company on the day of the lockout and found out probably about an hour and 45 minutes after the bargaining meeting that the lockout was taking place," Mr Jenkins said.
A Peabody spokesperson said Metropolitan Mine acknowledged that employees had engaged in industrial action, and the union had notified the company of further industrial action to come.
"In response, Peabody implemented employer response action, with a lockout of employees commencing night shift Wednesday, 18 June and continuing until day shift Thursday, 26 June," the spokesperson said.
The action follows a Federal Court decision last year ruling that 22 Peabody Energy crew members unjustly lost their jobs before being replaced by external contractors at the same mine in June 2020.
The court found that replacing full-time employees with labour hire did not constitute "genuine redundancies".
The lockout comes at a time when the nearby Tahmoor mine is also under pressure, but for a different reason, as the mine hasn't mined coal since February due to unpaid bills.
About 560 mineworkers are still being paid but have been stripped of their regular bonuses.
They are increasingly anxious about whether the mine, owned by British industrialist Sanjeev Gupta, and linked to the Whyalla steelworks, will reopen.
Independent Member for Wollondilly Judy Hannan said this week the state government was monitoring and negotiating with the mine's owner GFG Alliance.
The union has called for the state government to intervene.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
14 minutes ago
- News.com.au
Toyota GR Supra Supercar to be revealed in Sydney ahead of highly-anticipated 2026 debut
It has been 32 years since Toyota last featured on the Australian Touring car stage, but this will change in Sydney on September 1 when the highly-anticipated GR Supra is unveiled ahead of its official Supercars debut for the 2026 season. This year's Bathurst 1000 launch in the Harbour City will double as the exciting uncovering of the GR Supra Supercar. The Supercars faithful won't have to wait long to see it in the flesh either, with the GR Supra to make its trackside debut at this year's Bathurst 1000 from October 9-12. For loyal Toyota supporters – who have ingrained memories of the Corolla winning its class at Bathurst for eight straight years from 1985-1992 – the return of the popular brand to Superstars is a special moment. Supercars CEO James Warburton agrees, saying the unveiling of Toyota's weapon of choice marks a seismic moment for the Superstars as a sport. 'This is absolutely huge for Supercars,' Warburton said. 'Toyota joining the grid with the legendary GR Supra is a complete game-changer. This motorsport giant has incredible global pedigree and passionate Australian fans who are going to go wild seeing the Supra battle the Mustang and Camaro.' Brad Jones Racing (BJR) will be one of Toyota's two team partners for its entry into the 2026 Repco Supercars Championship. BJR will race four V8-powered GR Supra GEN3 Supercars from the upcoming 2026 season under a multi-year deal. The road to Supercars has been a long and calculated one for Toyota, whose factory-backed Toyota Gazoo Racing Australia (TGRA) program has built a reputation for success in grassroots motorsport, off-road rallying and circuit racing. Now, the company is ready to step onto the biggest stage in Australian racing with a car that's iconic across generations. 'The debut of the GR Supra Supercar at the upcoming Bathurst 1000 launch in Sydney marks a truly historic milestone for Toyota in Australian motorsport,' Toyota Australia Vice President of Sales, Marketing and Franchise Operations Sean Hanley said. 'GR Supra is a car synonymous with performance, passion and power, and as a race car, it makes an electrifying statement. This isn't just an arrival — it's our next bold step as we prepare to join the Supercars grid alongside the Mustang and Camaro in 2026. 'This moment is sure to ignite excitement among fans of Supercars, Toyota and Toyota Gazoo Racing across the nation. And the excitement will only build from here, with the GR Supra Supercar heading to this year's Bathurst 1000, where fans will have their first opportunity to get up close and personal with this absolute beast of a race car.' Warburton believes Toyota's unveiling at this year's Bathurst 1000 launch in Sydney couldn't be better. 'Launching in Sydney while kicking off the Bathurst 1000 countdown is absolutely perfect,' he said. 'It's going to be an incredible night — a triumphant celebration of everything that makes Supercars so spectacular.'
News.com.au
39 minutes ago
- News.com.au
Australian fashion retailer General Pants Co says they've settled $69,000 bill amid court threat
A well-known Australian fashion retailer will oppose a proposal to wind-up the business after it was hit with legal action over alleged debts, court documents reveal. General Pants Co was served with an insolvency claim on July 17 by supplier UCC Australia alleging the chain had failed to pay $69,835.92 owed for stock delivered. According to a winding up application filed in the Victorian Supreme Court, UCC Australia alleged it had unpaid invoices for the supply of cameras and film between October and December 2024. 'The goods were delivered and accepted by the debtor and the invoiced amounts remain due and payable,' the document states. The supplier sent General Pants Co a statutory demand for on June 17, requiring the alleged debt be paid within 21 days of service. According to the court documents, General Pants Co failed to comply with the demand, with UCC Australia seeking a court order for a liquidator to be appointed to the company. The matter has been listed before a Judicial Registrar on August 20. But in a two-page response filed with the court on July 24, lawyers acting for General Pants Co signalled their intention to appear at the hearing and oppose the application. The response claims the company opposes the application because the company is solvent and has paid UCC Australia's debt. General Pants Co has been a staple in Australian fashion for more than 50 years and has 55 stores across Australia and New Zealand. UCC is an importer, distributor and wholesaler of FMCG, supplying electricals and food to some of Australia's major retailers, including Myer, Big W, Kmart, Woolworths and Amazon.
News.com.au
44 minutes ago
- News.com.au
ASX Health Quarterly Wrap: Control Bionics makes 15pc sales revenue jump
As July draws to a close, today marks the official end of the June quarterly reporting period under ASX Listing Rules. These updates provide investors with a valuable snapshot of business momentum and future prospects with investors in healthcare watching signs of revenue growth, cash burn and future strategic direction. The June results are particularly pertinent as the last quarter of the financial year in Australia, providing an overview of the full year for many companies. Control Bionics (ASX:CBL) Control Bionics delivered a record year, with unaudited sales revenue rising 15% to more than $6 million and total revenue exceeding $7m in FY25. The company also reported an 8% lift in cash receipts, reaching $5.7m. During the quarter Control Bionics officially launched its NeuroNode Only sales model in the US following issuance of US Medicare reimbursement code E2513 under the Healthcare Common Procedure Coding System (HCPCS), locking in a rate of US$4300 (A$6600) per device. NeuroNode is a wearable, watch-like, wireless non-invasive electromyography (EMG) or spatial sensor device to assist people with physical disabilities perform everyday functions. Notably, this includes sufferers of cerebral palsy or motor neurone disease. Control Bionics said the US HCPCS reimbursement code laid the foundation for continued growth in the US, its largest addressable market. Discussions with multiple potential distribution partners in the US are well advanced. Control Bionics' Neuro Elite Athletics program NeuroBounce continues to gain commercial traction, diversifying its EMG technology into the sports performance market. Control Bionics has launched NeuroBounce in Australia with all five athletes in the initial four-week program improving their vertical jump height, with one recording an increase of 14 centimetres. Meanwhile, the company's NeuroNode device continues to gain traction in global markets. Following adoption within the UK's National Health Service (NHS), Control Bionics is now in active partnership discussions in both Europe and the US as it builds out its distribution-only strategy. In its NeuroStrip product line, Control Bionics has begun collecting EMG-labelled data from athletes and rehabilitation facilities with its development team now assessing opportunities to incorporate AI solutions to automate elements of the system. NeuroStrip hardware is now in use in both Australia and the US, with clinical evaluations underway across several areas. With growing international interest, expanding product lines, and a clear focus on commercialisation, Control Bionics said it had entered FY26 with strong momentum and multiple catalysts for further growth. Alterity Therapeutics (ASX:ATH) CEO and managing director Dr David Stamler said US Food and Drug Administration (FDA) fast track designation for ATH434 in multiple system atrophy (MSA) was the highlight of the recent quarter that also featured additional positive clinical data from its Phase 2 double-blind trial. "Receiving fast track designation alongside the orphan drug designation we have already received underscores the promise of this potentially disease-modifying therapy to address the urgent needs of individuals with MSA," he said. "In addition, we presented additional efficacy data from the ATH434-201 double-blind trial at prominent medical meetings, including slowing of disease progression on the Unified MSA Rating Scale or UMSARS, improvement in key symptoms of MSA, and preserved activity in the outpatient setting." Following quarter end Alterity this week announced positive results from its ATH434-202 open-label phase II clinical trial, in which ATH434 demonstrated a clinical benefit on the UMSARS and global assessments of neurological symptoms. Neuroimaging biomarkers showed target engagement and slowed brain atrophy in a manner consistent with the double-blind study findings with ATH434 continuing to demonstrate a favourable safety profile. "These data reinforce our confidence in the MSA program as we prepare for interactions with the US FDA," Stamler said. Alterity's cash position on June 30 was $40.66m, with operating cash outflows for the quarter of $2.35m. Neurotech International (ASX:NTI) Positive human PK study results for NTI164 released in June following preclinical toxicology results in May Data from Rett Syndrome program presented at the International Rett syndrome Foundation (IRSF) Annual Scientific Meeting Neurotech initiated formal engagement with US FDA in preparation for lodging an investigational new drug (IND) application in FY26 Neurotech's June quarter was marked by important clinical progress, growing international recognition, and further regulatory engagement for its lead investigational therapy NTI164, a proprietary CBDA-rich cannabinoid formulation being developed for paediatric neurological and inflammatory brain disorders. The company completed its first-in-human pharmacokinetic (PK) study. Conducted in healthy adult volunteers, the study confirmed that NTI164 is rapidly and predictably absorbed, with CBDA reaching peak plasma levels within 2–4 hours and emerging as the dominant circulating cannabinoid. Neurotech said the results validated NTI164's systemic stability, safety, and potential suitability for paediatric use. The PK study builds on preclinical toxicology results released in May, which demonstrated excellent tolerability in rats and dogs under GLP conditions. Neurotech also presented data from its Rett syndrome program at the International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting in Boston. Following the quarter, Neurotech announced that results from its phase I/II open-label clinical trial in Rett syndrome had been published in the Journal of Paediatrics and Child Health, a peer-reviewed scientific journal. Neurotech continued to progress its dual regulatory pathway strategy in Australia and the US during the quarter. In Australia, the company is moving toward potential product registration with the therapeutic Goods Administration (TGA) and is exploring expedited approval options to support timely market entry. The company has initiated formal engagement with the FDA in preparation for lodging an investigational new drug (IND) application in FY26. In June, Neurotech appointed leading US clinician Dr Bonni Goldstein as chief medical advisor USA, who has more than 25 years of clinical experience, including 17 years specialising in cannabinoid-based medicine. Goldstein is internationally recognised as a pioneer in paediatric cannabinoid therapy and brings key expertise as NTI164 progresses its development pathway. Also in June, CEO Dr Anthony Filippis attended the BIO International Convention in Boston as Neurotech continues to elevate its global profile and explore partnering and funding opportunities. Neurotech placed its wholly owned subsidiaries AAT Medical Ltd and AAT Research Ltd, responsible for the Mente neurofeedback device, into voluntary liquidation. The move reflects the company's focus on advancing NTI164. Operating cash outflows for the quarter were $2.6m, primarily driven by R&D expenditure supporting its FDA IND and TGA submissions, as well as clinical trial extension costs. Neurotech ended the period with $3m in cash and expects reduced outflows in Q1 FY26. A ~$3m R&D tax refund is anticipated in Q1 or early Q2 FY26 to further bolster cash reserves.
